These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 35211868)

  • 21. Measles, mumps, rubella prevention: how can we do better?
    Kauffmann F; Heffernan C; Meurice F; Ota MOC; Vetter V; Casabona G
    Expert Rev Vaccines; 2021 Jul; 20(7):811-826. PubMed ID: 34096442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Towards elimination of measles and rubella in Italy: Progress and challenges.
    Adamo G; Baccolini V; Massimi A; Barbato D; Cocchiara R; Di Paolo C; Mele A; Cianfanelli S; Angelozzi A; Castellani F; Salerno C; Isonne C; Bella A; Filia A; Del Manso M; Baggieri M; Nicoletti L; Magurano F; Iannazzo S; Marzuillo C; Villari P
    PLoS One; 2019; 14(12):e0226513. PubMed ID: 31841530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measles and rubella eradication in the Americas.
    Andrus JK; de Quadros CA; Solórzano CC; Periago MR; Henderson DA
    Vaccine; 2011 Dec; 29 Suppl 4():D91-6. PubMed ID: 22185837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Progress in the elimination of measles and rubella in the WHO European Region].
    Muscat M; Jankovic D; Goel A; Butler R; Pfeifer D
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1225-30. PubMed ID: 23990083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A microneedle patch for measles and rubella vaccination: a game changer for achieving elimination.
    Prausnitz MR; Goodson JL; Rota PA; Orenstein WA
    Curr Opin Virol; 2020 Apr; 41():68-76. PubMed ID: 32622318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating the future global dose demand for measles-rubella microarray patches.
    Ko M; Malvolti S; Cherian T; Mantel C; Biellik R; Jarrahian C; Menozzi-Arnaud M; Amorij JP; Christiansen H; Papania MJ; Meltzer MI; Masresha BG; Pastor D; Durrheim DN; Giersing B; Hasso-Agopsowicz M
    Front Public Health; 2022; 10():1037157. PubMed ID: 36726626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility assessment of measles and rubella eradication.
    Moss WJ; Shendale S; Lindstrand A; O'Brien KL; Turner N; Goodman T; Kretsinger K; ;
    Vaccine; 2021 Jun; 39(27):3544-3559. PubMed ID: 34045102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trend of measles-rubella vaccination coverage and impact on measles epidemiology in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.
    Rockson Adjei M; Longsignikuu A; Saeed Iddris I; Nang Suuri T; Asamoah B; Okoye M; Vanessa Baafi J; Kubio C; Ohene SA; Grobusch MP
    Vaccine; 2024 Mar; 42(8):1910-1917. PubMed ID: 38365480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The end of measles and congenital rubella: an achievable dream?
    Adamo G; Sturabotti G; D'Andrea E; Baccolini V; Romano F; Iannazzo S; Marzuillo C; Villari P
    Ann Ig; 2017; 29(1):1-26. PubMed ID: 28067934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of the revised World Health Organization cluster survey methodology to classify measles-rubella vaccination campaign coverage in 47 counties in Kenya, 2016.
    Subaiya S; Tabu C; N'ganga J; Awes AA; Sergon K; Cosmas L; Styczynski A; Thuo S; Lebo E; Kaiser R; Perry R; Ademba P; Kretsinger K; Onuekwusi I; Gary H; Scobie HM
    PLoS One; 2018; 13(7):e0199786. PubMed ID: 29965975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measles and Rubella Global Strategic Plan 2012-2020 midterm review.
    Orenstein WA; Hinman A; Nkowane B; Olive JM; Reingold A
    Vaccine; 2018 Jan; 36 Suppl 1():A1-A34. PubMed ID: 29307367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress in measles and rubella elimination in Iran.
    Esteghamati A; Gouya MM; Zahraei SM; Dadras MN; Rashidi A; Mahoney F
    Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The elimination of measles and rubella in Italy].
    Adamo G; Sturabotti G; De Soccio P; Prencipe GP; Sciarra I; Baccolini V; Massimi A; Marzuillo C; Iannazzo S; Villari P
    Ig Sanita Pubbl; 2017; 73(5):429-442. PubMed ID: 29433130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Country ownership as a guiding principle for IA2030: A case study of the measles and rubella elimination programs in Nepal and Nigeria.
    Wonodi C; Crowcroft N; Bose AS; Oteri J; Momoh J; Hughes G; Shet A; Pradhan R; Gautam JS; Jean Baptiste AE; Khanal S; Masresha B; Linstrand A
    Vaccine; 2024 Apr; 42 Suppl 1():S107-S117. PubMed ID: 37838480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Activities to catch up and Vaccinate the Susceptible Population in Valencian Community, Spain].
    Martín-Ivorra R; Alguacil-Ramos AM; Lluch-Rodrigo JA; Pastor-Villalba E; Portero-Alonso A
    Rev Esp Salud Publica; 2015; 89(4):419-26. PubMed ID: 26580797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress and challenges in measles and rubella elimination in the WHO European Region.
    Datta SS; O'Connor PM; Jankovic D; Muscat M; Ben Mamou MC; Singh S; Kaloumenos T; Reef S; Papania M; Butler R
    Vaccine; 2018 Aug; 36(36):5408-5415. PubMed ID: 28651838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [National immunization program initiatives-What are their contribution to the elimination of measles and rubella in Germany?].
    Kouros B; Nennstiel U; Liebl B; Ludwig MS
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2019 Apr; 62(4):386-391. PubMed ID: 30788537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effectiveness, population-level effects, and heath economics of measles and rubella vaccination].
    Wichmann O; Ultsch B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Sep; 56(9):1260-9. PubMed ID: 23990088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measles elimination: progress, challenges and implications for rubella control.
    Cutts FT; Lessler J; Metcalf CJ
    Expert Rev Vaccines; 2013 Aug; 12(8):917-32. PubMed ID: 23984961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.